IP Library › Granted Patent US 12,305,236
Granted Patent B2
US 12,305,236 · App. 17/051,731 · Granted May 20, 2025

Methods and systems for selection and treatment of patients with inflammatory diseases

Inventors: Janine Bilsborough (Simi Valley, CA); Dermot P. McGovern (Los Angeles, CA); Stephan Targan (Los Angeles, CA); Alka Potdar (Cumming, CA); Jeffry D. Watkins (Encinitas, CA); Cindy T. Dickerson (Encinitas, CA)
Assignees: Cedars-Sinai Medical Center; Prometheus Biosciences, Inc.
C12Q1/6883A61P1/00A61P37/06C07K16/2875A61K2039/505C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,305,236
App. No.
17/051,731
Granted
May 20, 2025
Kind
B2
Abstract

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

Claims (50)

1. A method of inhibiting or reducing CD30 ligand (CD30L) activity or expression in a subject having inflammatory bowel disease (IBD), the method comprising:

a) identifying the subject as being a carrier of a genotype comprising a polymorphism at rs911605 and/or rs1006026, wherein the polymorphism at rs911605 has an “A” allele at nucleobase 501 within rs911605 (SEQ ID NO: 1), and wherein the polymorphism at rs1006026 has a “G” allele at nucleobase 501 within rs1006026 (SEQ ID NO: 3); and

b) administering to the subject an effective amount of an inhibitor of CD30 ligand to inhibit or reduce the CD30 ligand activity or expression in the subject.

2. The method of claim 1 , wherein the genotype comprises the polymorphism at rs911605, and the polymorphism at rs1006026.

3. The method of claim 1 , wherein identifying the subject as being a carrier of the genotype comprises:

a) contacting a sample obtained from the subject comprising genetic material with a nucleic acid sequence capable of hybridizing to at least 10 contiguous nucleobases between nucleobase 400 and nucleobase 600 of at least one of SEQ ID NO: 1 and SEQ ID NO: 3 under standard hybridization conditions, wherein the at least 10 contiguous nucleobases comprises nucleobase at position 501 of the at least one of SEQ ID NO: 1 and SEQ ID NO: 3; and

b) detecting binding between the nucleic acid sequence and the at least 10 contiguous nucleobases between nucleobase 400 and nucleobase 600 of at least one of SEQ ID NO: 1 and SEQ ID NO: 3.

4. The method of claim 1 , wherein the inhibitor of CD30 ligand is an antibody or an antigen-binding fragment targeting CD30 ligand or CD30, or a combination thereof.

5. The method of claim 1 , wherein the inhibitor of CD30 ligand is an antibody or antigen-binding fragment thereof that specifically binds to CD30L, the antibody or antigen-binding fragment thereof comprising a heavy chain complementarity-determining region 1 (HCDR1), a heavy chain complementarity-determining region 2 (HCDR2), a heavy chain complementarity-determining region 3 (HCDR3), a light chain complementarity-determining region 1 (LCDR1), a light chain complementarity-determining region 2 (LCDR2), and a light chain complementarity-determining region 3 (LCDR3), wherein:

a. the HCDR1 comprises SEQ ID NO: 100, the HCDR2 comprises SEQ ID NO: 101, the HCDR3 comprises SEQ ID NO: 102, the LCDR1 comprises SEQ ID NO: 103, the LCDR2 comprises SEQ ID NO: 104, and the LCDR3 comprises SEQ ID NO: 105;

b. the HCDR1 comprises SEQ ID NO: 106, the HCDR2 comprises SEQ ID NO: 107, the HCDR3 comprises SEQ ID NO: 108, the LCDR1 comprises SEQ ID NO: 109, the LCDR2 comprises SEQ ID NO: 110, and the LCDR3 comprises SEQ ID NO: 111;

c. the HCDR1 comprises SEQ ID NO: 112, the HCDR2 comprises SEQ ID NO: 113, the HCDR3 comprises SEQ ID NO: 114, the LCDR1 comprises SEQ ID NO: 115, the LCDR2 comprises SEQ ID NO: 116, and the LCDR3 comprises SEQ ID NO: 117;

d. the HCDR1 comprises SEQ ID NO: 118, the HCDR2 comprises SEQ ID NO: 119, the HCDR3 comprises SEQ ID NO: 120, the LCDR1 comprises SEQ ID NO: 121, the LCDR2 comprises SEQ ID NO: 122, and the LCDR3 comprises SEQ ID NO: 123;

e. the HCDR1 comprises SEQ ID NO: 124, the HCDR2 comprises SEQ ID NO: 125, the HCDR3 comprises SEQ ID NO: 126, the LCDR1 comprises SEQ ID NO: 127, the LCDR2 comprises SEQ ID NO: 128, and the LCDR3 comprises SEQ ID NO: 129; or

f. the HCDR1 comprises SEQ ID NO: 130, the HCDR2 comprises SEQ ID NO: 131, the HCDR3 comprises SEQ ID NO: 132, the LCDR1 comprises SEQ ID NO: 133, the LCDR2 comprises SEQ ID NO: 134, and the LCDR3 comprises SEQ ID NO: 135.

6. The method of claim 1 , wherein the inhibitor of CD30 ligand is an antibody or antigen-binding fragment thereof that specifically binds to CD30L, the antibody or antigen-binding fragment thereof comprising a heavy chain variable domain (HC) and a light chain variable domain (LC), wherein:

a. the HC comprises SEQ ID NO: 136, and the LC comprises SEQ ID NO: 137;

b. the HC comprises SEQ ID NO: 138, and the LC comprises SEQ ID NO: 139;

c. the HC comprises SEQ ID NO: 140, and the LC comprises SEQ ID NO: 141;

d. the HC comprises SEQ ID NO: 142, and the LC comprises SEQ ID NO: 143;

e. the HC comprises SEQ ID NO: 144, and the LC comprises SEQ ID NO: 145;

f. the HC comprises SEQ ID NO: 146, and the LC comprises SEQ ID NO: 154;

g. the HC comprises SEQ ID NO: 147, and the LC comprises SEQ ID NO: 154;

h. the HC comprises SEQ ID NO: 148, and the LC comprises SEQ ID NO: 154;

i. the HC comprises SEQ ID NO: 149, and the LC comprises SEQ ID NO: 154;

j. the HC comprises SEQ ID NO: 150, and the LC comprises SEQ ID NO: 154;

k. the HC comprises SEQ ID NO: 151, and the LC comprises SEQ ID NO: 154;

l. The HC comprises SEQ ID NO: 152, and the LC comprises SEQ ID NO: 154; or

m. the HC comprises SEQ ID NO: 153, and the LC comprises SEQ ID NO: 154.

7. The method of claim 1 , wherein the inhibitor of CD30 ligand is an antibody that specifically binds to CD30L, the antibody comprising a heavy chain complementarity-determining region 1 (HCDR1), a heavy chain complementarity-determining region 2 (HCDR2), a heavy chain complementarity-determining region 3 (HCDR3), a light chain complementarity-determining region 1 (LCDR1), a light chain complementarity-determining region 2 (LCDR2), and a light chain complementarity-determining region 3 (LCDR3), wherein:

a. the HCDR 1 comprises SEQ ID NO: 100, the HCDR2 comprises SEQ ID NO: 101, the HCDR3 comprises SEQ ID NO: 102, the LCDR1 comprises SEQ ID NO: 103, the LCDR2 comprises SEQ ID NO: 104, and the LCDR3 comprises SEQ ID NO: 105;

b. the HCDR1 comprises SEQ ID NO: 106, the HCDR2 comprises SEQ ID NO: 107, the HCDR3 comprises SEQ ID NO: 108, the LCDRI comprises SEQ ID NO: 109, the LCDR2 comprises SEQ ID NO: 110, and the LCDR3 comprises SEQ ID NO: 111;

c. the HCDR1 comprises SEQ ID NO: 112, the HCDR2 comprises SEQ ID NO: 113, the HCDR3 comprises SEQ ID NO: 114, the LCDRI comprises SEQ ID NO: 115, the LCDR2 comprises SEQ ID NO: 116, and the LCDR3 comprises SEQ ID NO: 117;

d. the HCDR1 comprises SEQ ID NO: 118, the HCDR2 comprises SEQ ID NO: 119, the HCDR3 comprises SEQ ID NO: 120, the LCDR1 comprises SEQ ID NO: 121, the LCDR2 comprises SEQ ID NO: 122, and the LCDR3 comprises SEQ ID NO: 123;

e. the HCDR1 comprises SEQ ID NO: 124, the HCDR2 comprises SEQ ID NO: 125, the HCDR3 comprises SEQ ID NO: 126, the LCDR1 comprises SEQ ID NO: 127, the LCDR2 comprises SEQ ID NO: 128, and the LCDR3 comprises SEQ ID NO: 129; or

f. the HCDR1 comprises SEQ ID NO: 130, the HCDR2 comprises SEQ ID NO: 131, the HCDR3 comprises SEQ ID NO: 132, the LCDR1 comprises SEQ ID NO: 133, the LCDR2 comprises SEQ ID NO: 134, and the LCDR3 comprises SEQ ID NO: 135.

8. The method of claim 1 , wherein the inhibitor of CD30 ligand is an antibody that specifically binds to CD30L, the antibody comprising a heavy chain variable domain (HC) and a light chain variable domain (LC), wherein:

a. the HC comprises SEQ ID NO: 136, and the LC comprises SEQ ID NO: 137;

b. the HC comprises SEQ ID NO: 138, and the LC comprises SEQ ID NO: 139;

c. the HC comprises SEQ ID NO: 140, and the LC comprises SEQ ID NO: 141;

d. the HC comprises SEQ ID NO: 142, and the LC comprises SEQ ID NO: 143;

e. the HC comprises SEQ ID NO: 144, and the LC comprises SEQ ID NO: 145;

f. the HC comprises SEQ ID NO: 146, and the LC comprises SEQ ID NO: 154;

g. the HC comprises SEQ ID NO: 147, and the LC comprises SEQ ID NO: 154;

h. the HC comprises SEQ ID NO: 148, and the LC comprises SEQ ID NO: 154;

i. the HC comprises SEQ ID NO: 149, and the LC comprises SEQ ID NO: 154;

j. the HC comprises SEQ ID NO: 150, and the LC comprises SEQ ID NO: 154;

k. the HC comprises SEQ ID NO: 151, and the LC comprises SEQ ID NO: 154;

l. the HC comprises SEQ ID NO: 152, and the LC comprises SEQ ID NO: 154; or

m. the HC comprises SEQ ID NO: 153, and the LC comprises SEQ ID NO: 154.

Assignments (3)
SHARED INTEREST ASSIGNMENT 25% Recorded Jun 6, 2023
From: PROMETHEUS BIOSCIENCES, INC.
To: DR. FALK PHARMA GMBH
Reel/Frame 063881/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2021
From: BILSBOROUGH, JANINE; MCGOVERN, DERMOT P.; TARGAN, STEPHAN; POTDAR, ALKA
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 056827/0941 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2021
From: WATKINS, JEFFRY D.; DICKERSON, CINDY T.
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 056828/0104 →
Continuity (4)
Provisional Application 62784179 · Dec 21, 2018
Provisional Application 62681557 · Jun 6, 2018
Provisional Application 62664720 · Apr 30, 2018
Related Publication 20210238684A1 · Aug 5, 2021
References Cited (59)
US 4229447A · Porter · 1980 [cited by applicant]
US 4476116A · Anik · 1984 [cited by applicant]
US 4596795A · Pitha · 1986 [cited by applicant]
US 4755386A · Hsiao et al. · 1988 [cited by applicant]
US 5011692A · Fujioka et al. · 1991 [cited by applicant]
US 5017381A · Maruyama et al. · 1991 [cited by applicant]
US 5116817A · Anik · 1992 [cited by applicant]
US 5229135A · Philippon et al. · 1993 [cited by applicant]
US 5677430A · Goodwin et al. · 1997 [cited by applicant]
US 5739136A · Ellinwood, Jr. et al. · 1998 [cited by applicant]
US 5837284A · Mehta et al. · 1998 [cited by applicant]
US 5840329A · Bai · 1998 [cited by applicant]
US 5858401A · Bhalani et al. · 1999 [cited by applicant]
US 6391452B1 · Antonsen et al. · 2002 [cited by applicant]
US 6652854B2 · Mohler et al. · 2003 [cited by applicant]
US 6667048B1 · Lambert et al. · 2003 [cited by applicant]
US 6960563B2 · Egbaria et al. · 2005 [cited by applicant]
US 7122183B2 · Mohler et al. · 2006 [cited by applicant]
US 7273609B2 · Mohler et al. · 2007 [cited by applicant]
US 9926373B2 · Andersen et al. · 2018 [cited by applicant]
US 10322174B2 · Bilsborough et al. · 2019 [cited by applicant]
US 10562848B2 · Buchwald · 2020 [cited by applicant]
US 20020064527A1 · Mohler et al. · 2002 [cited by applicant]
US 20060194265A1 · Morris et al. · 2006 [cited by applicant]
US 20060280741A1 · Mohler et al. · 2006 [cited by applicant]
US 20080003221A1 · Podack · 2008 [cited by applicant]
US 20080213259A1 · Mohler et al. · 2008 [cited by applicant]
US 20080233119A2 · Podack · 2008 [cited by applicant]
US 20100071079A1 · Mohler et al. · 2010 [cited by applicant]
US 20120003182A1 · Abderrahim · 2012 [cited by examiner]
US 20120225427A1 · Mallat et al. · 2012 [cited by applicant]
US 20120328559A1 · Podack et al. · 2012 [cited by applicant]
US 20150056182A1 · Igawa et al. · 2015 [cited by applicant]
US 20160039940A1 · Andersen et al. · 2016 [cited by applicant]
US 20170166967A1 · Rotter et al. · 2017 [cited by applicant]
US 20180110855A1 · Bilsborough et al. · 2018 [cited by applicant]
US 20180298105A1 · Andersen et al. · 2018 [cited by applicant]
US 20190218309A1 · Igawa et al. · 2019 [cited by applicant]
CN 104540521A · 2015 [cited by applicant]
JP 2005503319A · 2005 [cited by applicant]
TW 201105662A · 2011 [cited by applicant]
WO WO2013081143A1 · 2013 [cited by applicant]
WO WO2013181694A1 · 2013 [cited by applicant]
WO WO2017106436A1 · 2017 [cited by applicant]
WO WO2019212899A1 · 2019 [cited by applicant]
Prometheus Biosciences, Inc. Amendment No. 1 to Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 8, 2021 (245 pages). [cited by applicant]
Prometheus Biosciences, Inc. Amendment No. 2 to Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 11, 2021 (245 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10K Annual Report as filed with the Securities and Exchange Commission on Feb. 28, 2023 (129 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10K Annual Report as filed with the Securities and Exchange Commission on Mar. 9, 2022 (125 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10-K/A Annual Report (Amendment No. 1) as filed with the Securities and Exchange Commission on Apr. 28, 2023 (42 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 11, 2021 (4 pages). [cited by applicant]
European Patent Application No. 19796203.8 Extended European Search Report dated Jan. 14, 2022. [cited by applicant]
Fava et al.: Association of TNFSF8 Regulatory Variants With Excessive Inflammatory Responses but not Leprosy Per Se. Journal of Infectious Diseases. 211(6):968-977. (2015). [cited by applicant]
Nakamura et al.: Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population. The American Journal of Human Genetics. 91(4):721-728 (2012). [cited by applicant]
Li et al.: Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease. Gastroenterology; 150(5):1196-1207 (2016). [cited by applicant]
PCT/US2019/029402 International Search Report and Written Opinion dated Sep. 3, 2019. [cited by applicant]
PCT/US2019/029402 International Preliminary Report on Patentability dated Nov. 12, 2020. [cited by applicant]
Prometheus Biosciences, Inc. Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Feb. 19, 2021 (246 pages). [cited by applicant]
Singh et al. Encyclopedia of Pharmaceutical Technology 2nd Ed. pp. 754-757 (2002). [cited by applicant]